References
- Johns Hopkins Coronavirus Resource Center. (n.d.). JHU CSSE COVID. Johns Hopkins University & Medicine. [cited 2022 Jun 14] Available from: https://coronavirus.jhu.edu/map.html
- Ritchie H, Mathieu E, Rodés-Guirao L, et al. (2020) “Coronavirus Pandemic (COVID-19)”. Published online at OurWorldInDataorg. [cited 2022 Mar 5] Available from: https://ourworldindata.org/coronavirus
- Cumulative confirmed COVID-19 cases per million people. [ cited 2022 March 5] Available from: https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01.latest&facet=none&pickerSort=asc&pickerMetric=location&Metric=Confirmed±cases&Interval=Cumulative&Relative±to±Population=true&Color±by±test±positivity=false&country=USA~GBR~CAN~DEU~ITA~IND~HKG~CHN~MYS~SGP~THA~IDN~PHL~VNM~MMR~KHM
- U.S. Centers for Disease Control and Prevention. COVID data tracker (Variant proportions). [cited 2022 Jun 14] Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions
- European Centre for Disease Prevention and Control. Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA. [cited 2022 Jun 14] Available from: https://www.ecdc.europa.eu/en/news-events/implications-emergence-spread-sars-cov-2-variants-concern-ba4-and-ba5
- 2022 Multilateral Leaders Task Force on COVID-19. Lower middle income countries. [cited 2022 Jun 14] Available from: https://data.covid19taskforce.com/data/lower-middle-income
- Share of people who received at least one dose of COVID-19 vaccine. [cited 2022 Mar 5] Available from: https://ourworldindata.org/grapher/share-people-vaccinated-covid
- WHO South-East Asia Region Weekly COVID-19 Situational Report. 10 Mar - 16 Mar 22, Week 10, 2022. [cited 2022 Mar 24] Available from: https://cdn.who.int/media/docs/default-source/searo/whe/coronavirus19/sear-weekly-reports/searo-weekly-situation-report-10-2022.pdf?sfvrsn=7b78d984_5
- Operational Response to COVID-19 (Coronavirus) in East Asia and the Pacific. World Bank Brief. cited 2021 Dec 22. https://www.worldbank.org/en/region/eap/brief/world-banks-operational-response-to-covid-19-coronavirus-in-east-asia-and-the-pacific
- Fleming M, Okebukola P, Skiba K Port to patient: improving country cold chains for COVID-19 vaccines. [cited 2022 Apr 7] Available from: https://www.mckinsey.com/industries/public-and-social-sector/our-insights/port-to-patient-improving-country-cold-chains-for-covid-19-vaccines
- Tagoe ET, Sheikh N, Morton A, et al. COVID-19 vaccination in lower-middle income countries: national stakeholder views on challenges, barriers, and potential solutions. Front Public Health. 2021;9:709127.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385:585–594.
- Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study. [cited 2022 Apr 8] Available from: https://ssrn.com/abstract=4005130
- Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614–1621.
- Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646–1657.
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
- Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. Bmj. 2021;374:n1943.
- Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829.
- Pawlowski C, Lenehan P, Puranik A, et al. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (NY). 2021;2(8):979–992.e8.
- International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub. www.view-hub.org. Accessed 2022 March 22.
- Higdon MM, Wahl B, Jones CB, et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. medRxiv 2021.09.17.21263549; 10.1101/2021.09.17.21263549
- Suah JL, Tok PSK, Ong SM, et al. PICK-ing Malaysia’s epidemic apart: effectiveness of a diverse COVID-19 vaccine portfolio. Vaccines (Basel). 2021;9(12):1381. Published 2021 Nov 24.
- Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, et al., Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11(1):585–592.
- Thailand Department of Disease Control, Ministry of Public Health. Retrieved on 2022 Apr 11, from: https://www.facebook.com/photo/?fbid=1861970633989147&set=a.484135618439329
- Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant [published online ahead of print, 2022 Mar 2]. N Engl J Med. 2022. 10.1056/NEJMoa2119451.
- UK Health Security Agency. Research and analysis COVID-19 vaccine weekly surveillance reports (weeks 39 to 13, 2021 to 2022). [cited 2022 Apr 7] Available from: https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9ed25929-064b-4b0e-8cbb-cae7639135d7&utm_content=daily
- Suah JL, Husin M, and Keng PS, et al. Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study [published online ahead of print, 2022 Mar 21]. Int J Infect Dis. 2022 119 ;69–76.
- Hirschmann R Vaccination rate against COVID-19 Malaysia 2022, by state. [cited 2022 Mar 7] Available from: https://www.statista.com/statistics/1270638/malaysia-covid-19-vaccination-rate-by-state/29.
- Effectiveness of COVID-19 Vaccines Update 14 January, 2022. Department of Disease Control, Thailand Ministry of Public Health. [cited 2022 Mar 22] Available from: https://www.facebook.com/photo/?fbid=1861970633989147&set=a.484135618439329
- COVID-19 Vaccine Tracker. Sinovac: coronaVac. Available online: https://covid19.trackvaccines.org/vaccines/7/ (accessed on 2021 Oct 10).
- World Health Organization. Evidence assessment: sinovac/CoronaVac COVID-19 vaccine [cited 27 March 2022]. Available online: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf
- Burn E, Li X, Kostka K, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID −19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf. 2022;31:495–510. Epub ahead of print. PMID: 35191114.
- Soboleva K, Shankar NK, and Yadavalli M, et al., Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination. Lancet Global Health. 2022;10(January 2022):e33–e34.
- Vaccines against Covid-19, venous thromboembolism, and thrombocytopenia. A population-based retrospective cohort study. Laporte JR, Coma E, Fina F, et al. medRxiv 2021.07.23.21261036; 10.1101/2021.07.23.21261036. Accessed 2022 Mar 23.
- Whiteley WN, Ip S, Cooper JA, et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England. PLoS Med. 2022;19(2):e1003926. Published 2022 Feb 22.
- McMahan K, Yu J, Nb M, et al., Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634.
- Kerr S, Joy M, Torabi F, et al. First dose AZD1222 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales. PLoS Med. 2022;19(2):e1003927.
- de Gregorio C, Colarusso L, Calcaterra G, et al., Cerebral venous sinus thrombosis following COVID-19 vaccination: analysis of 552 worldwide cases. Vaccines (Basel). 2022;10(2):232.
- Sa S, Lee CW, Shim SR, et al., The safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 vaccines: safety monitoring for adverse events using real-world data. Vaccines (Basel). 2022;10(2):320.
- Somiya M, Mine S, Yasukawa K, et al. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021;39(25):3313–3314.
- McNeil MM, Weintraub ES, Duffy J, et al., Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–878.
- Hajjo R, Sabbah DA, Bardaweel SK, et al. Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients. Vaccines (Basel). 2021;9(10):1186. Published 2021 Oct 15.
- European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021
- Centers for Disease Control and Prevention. Morbidity and mortality weekly report. Retrieved on Apr 11, 2022 from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm
- Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN. 2021. 10.2139/ssrn.3822780.
- Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–2276.
- No evidence that Covid-19 booster shots ‘increase risk of lymphoma and autoimmune diseases.’ AFP Fact Check. [cited 2022 Apr 6] Available from: https://factcheck.afp.com/http%253A%252F%252Fdoc.afp.com%252F9QW7NY-1
- McLean G, Kamil J, Lee B, et al. The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines [published online ahead of print, 2022 Mar 30]. mBio. 2022;13:e0297921.
- Balkan İİ, Dinc HO, Can G, et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required [published online ahead of print, 2022 Mar 28]. Ir J Med Sci. 2022;191:1–7.
- Yue L, Xie T, Yang T, et al. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine. J Med Virol. 2022;94(1):35–38.
- Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination [published online ahead of print, 2022 Mar 10]. J Infect Dis. 2022:jiac092. 10.1093/infdis/jiac092.
- Glatman-Freedman A, Bromberg M, Hershkovitz Y, et al. Effectiveness of BNT162b2 vaccine booster against SARS-CoV-2 infection and breakthrough complications, Israel [published online ahead of print, 2022 Apr 1]. Emerg Infect Dis. 2022;28(5):948–956.
- Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211.
- Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–2040.
- Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50.
- Barin B, Kasap U, Selçuk F, et al. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022;3(4):e274–e283.
- Szczepanek J, Skorupa M, Goroncy A, et al. Anti-SARS-CoV-2 IgG against the S protein: a comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S vaccines. Vaccines (Basel). 2022;10(1):99.
- Wang L, Davis PB, Kaelber DC, et al. Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalisations, and death during the delta-predominant period. JAMA. 2022;327(7):678–680.
- Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose [published correction appears in Lancet. 2022 Feb 12;399(10325):628]. Lancet. 2022;399(10325):625–626.
- Paniskaki K, Anft M, Meister TL, et al. Immune response in moderate to critical breakthrough COVID-19 infection after mRNA vaccination. Front Immunol. 2022;13:816220.
- Gallais F, Gantner P, Planas D, et al. Case report: evolution of humoral and cellular immunity in two COVID-19 breakthrough infections after BNT162b2 vaccine. Front Immunol. 2022;13:790212.
- Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474–1484.
- Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: b cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80:1345–1350.
- Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340–350.
- Nordström P, Ballin M, and Nordström A, Effectiveness of Covid-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study [cited 25 April 2022]. Available at: http://dx.doi.org/10.2139/ssrn.3949410
- Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21(6):395–404.
- The MP. T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186–193.
- Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880.
- Juno JA, Tan HX, Lee WS, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020;26(9):1428–1434.
- Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19.
- Malli F, Lampropoulos IC, Papagiannis D, et al. Association of SARS-CoV-2 vaccinations with SARS-CoV-2 infections, ICU admissions and deaths in greece. Vaccines (Basel). 2022;10(2):337.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the AZD1222 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet. 2021 Jan 9;397(10269):98]. Lancet. 2021;397(10269):99–111.
- Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384(16):1576–1577.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
- UK Health Security Agency: COVID-19 Vaccine Surveillance Report. Week 12 (24 March 2022). [cited 2022 Mar 31] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillance-report-week-12.pdf
- UK Health Security Agency: Research and analysis. COVID-19 vaccine weekly surveillance reports (weeks 39 to 12, 2021 to 2022). Data on the real-world effectiveness and impact of the COVID-19 vaccines. Retreived on 2022 Mar 31, from: https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9ed25929-064b-4b0e-8cbb-cae7639135d7&utm_content=daily
- Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. medRxiv 2022.03.13.22272308. Retrieved on 2022 Apr 1 from: https://www.medrxiv.org/content/10.1101/2022.03.13.22272308v1.full (Preprint)
- Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron variant from previous SARS-CoV-2 Infection. N Engl J Med. 2022;386(13):1288–1290.
- Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis. 2022;22:791–801. Published Online 2022 Mar 31.
- Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), 08 March 2022. World Health Organization. [cited 2022 Apr 6] Available from: https://www.who.int/news/item/08-03-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-08-march-2022
- Chu DT, Singh V. Obesity and hypertension in Asia: current status and challenges. Lancet Reg Health West Pac. 2021;15:100243.
- Callaway E. COVID vaccine boosters: the most important questions. Nature. 2021;596(7871):178–180.
- Krause PR, Fleming TR, Peto R, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398(10308):1377–1380.
- Deming ME, Lyke KE. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nat Med. 2021;27(9):1510–1511.